

A. Amendments to the Specification:

1. (cancelled)

2. (cancelled)

3. (currently amended) A medicament for correction of pathologic immune reaction based on antibodies to tumor necrosis factor alpha (TNF- α) characterized by the presence of an activated form of antibodies to TNF- α , said antibodies being a mixture of C50, C200 and C1000 dilutions obtained by multiple consecutive dilutions and exposure to external factors, preferably following the homeopathic technology.

4. (previously presented) A medicament according to claim 3 characterized by obtaining antibodies with the use of human or heterologous tumor necrosis factor alpha (TNF- α), including a recombinant factor.

5. (previously presented) A medicament according to claim 3 characterized by containing a mixture of various, mostly centesimal homeopathic dilutions.